EOLS — EVOLUS INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
EOLS FAQ
What is EOLS's P/E ratio?
EVOLUS INC (EOLS) currently trades at a P/E ratio of 3,378.86.
What is EOLS's ROE?
EVOLUS INC reports a Return on Equity (ROE) of 150.87%.
What is EOLS's dividend yield?
EVOLUS INC offers a dividend yield of 0.00%.
What is EOLS's Deepscope Quality Score?
Deepscope rates EOLS's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy EOLS?
Deepscope's AI Timing Score for EOLS is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does EOLS belong to?
EVOLUS INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 6.70
Price
0.02
(0.30%)
Day Change
|
|
|---|
EOLS Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 31) nhưng Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ P/E tương đối cao
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
ROE đang giảm đáng kể
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 6.70 |
| PBV / Sector |
-15.26 / 2.60
|
| Earning Per Share | -0.66 |
| PE / Sector |
3,378.86 / 23.51
|
| PEG or PE/Growth / Sector |
-226.31 / 0.13
|
| Average 1M Daily Value |
4.64 M
GREAT
|
| Average 1W Daily Value |
5.07 M
GREAT
|
| Yếu tố Kỹ thuật |
|
71% |
| Sức khỏe tài chính |
|
41% |
| Khả năng kiếm lợi nhuận |
|
56% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-10 09:43:05 |
| Symbol | EOLS |
| Name | EVOLUS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 65.85 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 439.25 / 9,783.97 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 520 Newport Center Drive, Newport Beach, CA, United States, 92660
Phone: 949 284 4555
Website: https://www.evolus.com
Employees: 350
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google